BPMC - Blueprint Medicines Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
80.90
+1.50 (+1.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close79.40
Open79.19
Bid80.95 x 800
Ask81.00 x 1000
Day's Range78.85 - 81.34
52 Week Range44.58 - 102.98
Volume368,260
Avg. Volume440,053
Market Cap3.973B
Beta (3Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-7.52
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est112.09
Trade prices are not sourced from all markets
  • Does Blueprint Medicines Corporation (NASDAQ:BPMC) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does Blueprint Medicines Corporation (NASDAQ:BPMC) Have A Particularly Volatile Share Price?

    If you own shares in Blueprint Medicines Corporation (NASDAQ:BPMC) then it's worth thinking about how it contributes...

  • Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
    Zacks

    Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

    Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.

  • 4 Biotech Stocks With Big Catalysts in September
    Motley Fool

    4 Biotech Stocks With Big Catalysts in September

    Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.

  • Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?
    Zacks

    Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?

    Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Blueprint Medicines to Present at Upcoming Investor Conferences in September
    PR Newswire

    Blueprint Medicines to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass. , Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  ...

  • GuruFocus.com

    Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $1.6 million of Shares

    CEO and President of Blueprint Medicines Corp (30-Year Financial, Insider Trades) Jeffrey W. Albers (insider trades) sold 20,000 shares of BPMC on 08/19/2019 at an average price of $81.73 a share. Continue reading...

  • This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival
    Investor's Business Daily

    This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival

    Deciphera Pharmaceuticals continued a two-day sprint Wednesday on excitement over a stomach cancer treatment, but at least one analyst far prefers rival biotech company Blueprint Medicines.

  • Deciphera stock surges on gastrointestinal cancer drug success
    American City Business Journals

    Deciphera stock surges on gastrointestinal cancer drug success

    After sixteen years of work, Waltham drugmaker Deciphera Pharmaceuticals Inc. is set to ask the FDA for permission to bring its first product to market next year.

  • Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
    PR Newswire

    Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

    CAMBRIDGE, Mass., Aug. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for avapritinib for the treatment of adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, and fourth-line GIST. The FDA granted Priority Review and set an action date of February 14, 2020 under the Prescription Drug User Fee Act (PDUFA).

  • The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund
    GuruFocus.com

    The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund

    Health care-focused fund releases 2nd-quarter portfolio Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of BPMC earnings conference call or presentation 1-Aug-19 12:30pm GMT

    Q2 2019 Blueprint Medicines Corp Earnings Call

  • Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
    PR Newswire

    Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference

    CAMBRIDGE, Mass. , Aug. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  ...

  • 3 Lung Cancer Stocks That Could Soar in September
    Motley Fool

    3 Lung Cancer Stocks That Could Soar in September

    These industry giants could make big moves after this year's World Conference on Lung Cancer.

  • Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
    Zacks

    Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

    Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

  • Blueprint Medicines (BPMC) Q2 2019 Earnings Call Transcript
    Motley Fool

    Blueprint Medicines (BPMC) Q2 2019 Earnings Call Transcript

    BPMC earnings call for the period ending June 30, 2019.

  • Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

    Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -6.25% and 80.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Blueprint Medicines Reports Second Quarter 2019 Financial Results
    PR Newswire

    Blueprint Medicines Reports Second Quarter 2019 Financial Results

    -- NDA and MAA submitted for avapritinib for defined GIST patient populations -- -- Updated data presented for avapritinib and pralsetinib (formerly BLU-667) to support planned NDA submissions in 2020 ...

  • Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
    PR Newswire

    Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019

    CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...

  • 5 Biotech Stocks to Buy for a Strong Growth Prognosis
    InvestorPlace

    5 Biotech Stocks to Buy for a Strong Growth Prognosis

    Biotech stocks have to be the ultimate risk and reward equities. No other sector comes close to the return potential of the sector. Just take a look at the gains for the SPDR S&P Biotech ETF (NYSE:XBI). The ETF and sector benchmark has managed to post average annual returns of nearly 19% over the last decade. That's pretty insane and underscores the kind of potential that biotech stocks can have.But they also come with a ton of risk to get that return. They don't call them lotto tickets for anything. Many biotech stocks are just one bad trial away from crashing, burning and causing plenty of heartache for their shareholders.However, there are ways to hedge your bets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAside from going into a broad ETF like the XBI, the key is making sure that investors focus on developmental pipelines, partnership and plenty of cash on their balance sheets. Having a drug actually in the marketing stages doesn't hurt either. It's here that investors can find success in the sector. * 10 Stocks to Buy From This Superstar Fund With that in mind, here are five biotech stocks that have plenty of potential. Galapagos NV (GLPG)Source: Shutterstock A good way to spot top clinical-stage and early-entry biotech stocks is finding those firms with top-notch partners. And Galapagos NV (NASDAQ:GLPG) couldn't have picked a better partner than biotech royalty Gilead Sciences (NASDAQ:GILD). GILD recently upped its partnership stake in GLPG via a nearly $4 billion payment as well as a $1.1 billion equity stake. All in all, Gilead will now own 22% of Galapagos.There's a good reason why GILD would want to pony up that kind of cash for the biotech firm. It needs to fill potential revenue holes in its aging pipeline and GLPG has the goods.Galapagos has one of the richest and largest development pipelines around. The drug company has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. This includes its potential blockbuster in Filgotinib. This was the first partnership with Gilead and after impressive phase-3 data for the rheumatoid arthritis drug, the duo expects to submit a marketing application with the FDA at the end of the year. Meanwhile, successful initial idiopathic pulmonary fibrosis data, as well as beginning trials for new cystic fibrosis medicines, could all bare significant fruit for GLPG.That's an impressive amount of "shots on goal" for a clinical-stage biotech stock. The best part is, based on the rich deal, the speculation is that Galapagos wanted to stay independent rather than receive a full buyout from GILD. This means it can make the full use of that pipeline with future royalty and milestone payments. It also means investors in GLPG stock can as well. Blueprint Medicines (BPMC)Source: Shutterstock There are a few mega-trends in the world of biotech stocks. Gene therapy is a major one. Another is the concept of small-molecule drugs. Small-molecule drugs are generally more stable than their biologic counterparts and can more commonly be taken as pills as opposed to injections. Though some injected biologics can be taken outside of a healthcare setting (notably Abbvie's (NYSE:ABBV) Humira), many need to be administered by a doctor, nurse or other medical professional. This makes small-molecule drugs better for accessibility and ongoing treatments.This focus on small-molecule drugs makes Blueprint Medicines (NASDAQ:BPMC) a potential real winner among the biotech stocks.BPMC current roster of developmental drugs focuses on various cancers. And the beauty is that pill-delivery system. It really works. Avapritinib -- which treats systemic macrocytosis (SM) and gastrointestinal stromal tumors (GIST) -- managed to shrink these tumors in 86% of the patients treated. That's big any study. The late trial success allowed Blueprint to a marketing application to the FDA for it. The firm has also seen great success targeting other cancers in several other early trials -- with the small -molecule delivery system leading the way. * 7 Stocks to Sell This Summer Earnings Season These successes allowed BPMC to plot its course of action for next year. That should include two marketed drugs, four in application stages and more than a dozen in trials and preclinical investigation. Given the wins already, there's no reason to think blueprint won't get there. Ligand Pharmaceuticals (LGND)Source: Shutterstock If one partner is good, then having over a hundred is better. And this is the case for Ligand Pharmaceuticals (NASDAQ:LGND). LGND counts big shots like Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE) and generic drug specialist Teva (NASDAQ:TEVA) as some of partners/ licensees. The key is Ligand's business model.Ligand doesn't actually develop drugs itself. What it does is provide development platforms that help other biotech stocks and pharmaceutical companies create drugs more effectively. That huge difference has allowed Ligand to quietly become one of the sector's secret stars. Ligand gets upfront payments, development milestones and backend payments on sales after the drugs hit the marketing stages. So far, 10 drugs are now being sold using Ligand's tech. But more are in the late stages of trials.Perhaps the best part is much of the development risk is pushed on the firms using LGND's tech. Ligand gets paid something either way.As a result, LGND is one of the few biotech stocks out there that is actually profitable. Moreover, the steady stream of royalties has allowed the firm to build up a massive war chest of more than $1.4 billion in cash on its balance sheet. While it's too early to talk about dividend potential, LGND could be on its way to initiating a payout in the future as more drugs hit pharmacy shelves using its technology.And yet, shares of LGND could be a massive bargain. After some hype has left the stock, investors can score shares about 505 below peaks hit last summer. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Dominating a disease can mean some big-time revenues for biotech stocks. When it comes to cystic fibrosis, Vertex Pharmaceuticals (NASDAQ:VRTX) is pretty much the only game in town. It's three FDA-approved drugs -- Kalydeco, Orkambi, and Symdeko -- have a monopoly on the disease.]This massive foothold on cystic fibrosis treatments have made VRTX a cash cow for investors. Last year, Vertex managed to sell more than $3 billion worth of medicines to treat the disease. However, this year is looking to eclipse that rate. Already for the first quarter of 2019, VRTX managed to pull in nearly $900 million in revenues alone. That puts it on track reap more than $5 billion in annual sales by 2024. Those robust sales have also helped balloon its cash balance to more than $3.5 billion at the end of the quarter.And the future is robust for Vertex as well.The firm is working on a proved combination therapy of its three drugs to help boosts further, while Symdeko recently received approval from the FDA to be used in children. The best news for VRTX could be a recent foray into gene editing that could treat cystic fibrosis completely. Partnering with CRISPR Therapeutics (NASDAQ:CRSP), Vertex recently started the first human trial using a CRISPR-based product. That drug -- CTX001 -- also received FDA fast track status and could be a huge revenue booster if approved. * 7 Great Sector ETFs to Buy for the Short or Long Term With its strong dominance, hefty cash flows and continued sales increases, VRTX has quickly become one of biotech's brightest stars. BioMarin Pharmaceuticals (BRMN)Source: Shutterstock Thanks to continued advances in science and technology, we're able to tackle more rare and orphan diseases. And thanks to their generally small patient population sizes and difficulty of treatment, drugs targeting this niche of the market often come with sky-high prices. For biotech stocks like BioMarin Pharmaceuticals (NASDAQ:BMRN) this is a revenue win.BRMN has made a name for itself as by only targeting rare diseases and has the most success in this area. The firm currently has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. BioMarin has continued to see rising sales and prescriptions for these medications. For example, during the last quarter, the trio of Vimizim, Kuvan, and Naglazyme managed to generate year-over-year revenue growth of 7%, 8%, and 16%, respectively. All in all, total revenues for BRMN topped more than $400 million for the first quarter alone.And those revenues could keep soaring into the future.For one thing, rare disease medications often come with longer exclusivity rights. This gives BMRN a very long runway to ward off generic competition. Secondly, rare disease medications generally have no trouble getting covered by health insurers. This allows patients to actually get their hands on the high-priced meds in the first place.Adding in BioMarin's beefy pipeline and you have a recipe for success. Analysts expect the firm to finally start turning a profit by 2020 -- especially if its new hemophilia drug turns out to be a blockbuster.Disclosure: At the time of writing, Aaron Levitt was Long CRSP and the iShares NASDAQ Biotechnology ETF (IBB) -- which owns all the stocks on this list. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy From This Superstar Fund * 7 Stocks to Buy This Summer Earnings Season * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk The post 5 Biotech Stocks to Buy for a Strong Growth Prognosis appeared first on InvestorPlace.

  • Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
    PR Newswire

    Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST

    CAMBRIDGE, Mass., July 18, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) for avapritinib for the treatment of adult patients with PDGFRα D842V mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, and fourth-line GIST. Avapritinib is an investigational, potent and highly selective KIT and PDGFRA inhibitor for patients with advanced GIST.

  • 3 Soaring Biotech Stocks With More Fuel in the Tank
    Motley Fool

    3 Soaring Biotech Stocks With More Fuel in the Tank

    Despite already massive gains this year, shares of these drugmakers could keep on climbing.

  • Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019
    Motley Fool

    Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019

    It looks like this biotech has what big-pharma companies have been eager to acquire.

  • Has Blueprint Medicines Corporation (NASDAQ:BPMC) Got Enough Cash?
    Simply Wall St.

    Has Blueprint Medicines Corporation (NASDAQ:BPMC) Got Enough Cash?

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Blueprint...

  • 2 Stocks That Could Be the Next Biotech Buyouts
    Motley Fool

    2 Stocks That Could Be the Next Biotech Buyouts

    Here's why these very different drugmakers could both receive a big buyout offer before the end of 2019.

  • The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
    Zacks

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure